David H Wang

David H Wang sells 100,002 shares of ACMR for $8.8M across 11 transactions, scheduled via 10b5-1 plan adopted 2024-11-29.

David H Wang executed 11 separate sales totaling 100,002 shares for $8,835,388.38 at a blended average price of $88.35, reducing his non-derivative holdings from 902.7K to 802.7K shares. This transaction is scheduled under a pre-arranged 10b5-1 trading plan adopted on 2024-11-29, eliminating discretionary timing as a factor. The insider retains substantial derivative holdings of 580,002 shares (310,002 from one stock option grant and 270,000 from another). Prior sales by this insider at ACMR (completed 2026-03-11 and 2026-03-12) showed 30-day returns ranging from -0.6% to +7.0%, with consistent 90-day gains between +86.6% and +100.8%, suggesting the stock appreciated following recent prior sales. The current stock price of $76.29 is 19.0% below the 52-week high of $94.21, trading well below the average execution price of $88.35 achieved in this filing.

David H Wang sold 110,000 ACMR shares for $5.2M (blended avg $46.86) across 5 transactions on March 11–12, 2026.

Wang executed 5 separate sales totaling 110,000 shares for $5,154,404.79, reducing his holdings from 912.7K to 802.7K shares (-12.1%). The sales occurred at prices between $44.92 and $48.34, slightly above the current market price of $46.38 and well below the 52-week high of $70.68. Wang's prior trades at ACMR show a concerning pattern: all 5 prior sells have resulted in positive 90-day returns (ranging from +28.4% to +57.2%), meaning the stock rose after each sale—a 0% well-timed rate at this ticker. His cross-ticker track record shows a 35% well-timed rate with an average 90-day return of +16.7% after sells. The current sale occurs while the stock is down 34.4% from its 52-week high, yet the company shows solid fundamentals (P/E of 6.11, +15.2% annual revenue growth, $35.9M net income on $269.2M revenue). The consistent pattern of subsequent gains following his prior ACMR sales, combined with the current depressed valuation relative to recent highs, suggests this sale does not reflect a well-established timing advantage.

David H Wang sold 130,000 shares ($4.4M) at ACM Research via pre-arranged 10b5-1 plan.

David H Wang executed 4 separate sales totaling 130,000 shares for $4,361,476.70 across December 3–4, 2025, at prices ranging from $33.05 to $34.42 (blended average $33.55). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-29, making it scheduled rather than discretionary. Post-transaction holdings of 802,708 shares represent a 13.9% reduction from pre-transaction holdings of 932,708 shares. Because the trade is scheduled under 10b5-1, it reflects a pre-established divestment commitment rather than a response to current market or business conditions.

Wang sold 130,000 ACMR shares for $3.5M at $26.61 avg; 2 of 5 prior ACMR sells were well-timed at 90d.

Wang David H executed 3 separate sales totaling 130,000 shares for $3,459,786.94 on 2025-09-03 and 2025-09-04, reducing his holdings by 16.2% from 802,708 shares to 672,708 shares. The sales occurred at an average price of $26.61, near the current price of $27.41 and within the 52-week range of $14.10–$32.06. Examining his prior trades at ACMR, Wang's track record shows mixed timing: 2 of 5 prior sells achieved negative 90-day returns (well-timed, with declines of 29.5%–30.4% in the 30-day window after those trades), while 3 prior sells were followed by gains (poorly timed from a sell-side perspective, with 90-day returns between 1.6% and 11.2%). His cross-ticker sell history shows an average 90-day return of +0.7% with a 60.00% well-timed rate, indicating moderate accuracy in broader sell decisions. The company's fundamentals remain solid: $215.4M revenue, $29.8M net income, 40.2% annual revenue growth, and a P/E of 3.47, suggesting underlying business strength despite the recent insider sale activity.

ACMR CFO sells 130,000 shares across 3 trades for $3.0M; stock now -25.2% from 52-week high

David H Wang sold 130,000 shares (130.0K shares) in three separate transactions on 2025-05-21 and 2025-05-22 for $3,009,803.52, reducing his holdings from 802.7K to 672.7K shares (-16.2%). The blended average price of $23.15 places these sales near the stock's current level of $22.41, which is -25.2% from its 52-week high of $29.98. Wang's prior sales at ACMR (five trades since November 2024) have shown consistent negative 30-day returns ranging from -14.5% to -30.7%, with only one prior 90-day outcome measurable (a +28.3% gain), suggesting this insider's timing has not been well-calibrated at this ticker. The company's fundamentals remain solid—revenue $172.3M, annual growth of +40.2%, net income $20.4M, and P/E of 2.98—indicating the sale does not reflect deterioration in core operations. The stock has gained +13.6% over 30 days despite the recent pullback, and Wang retains substantial holdings (672.7K shares), which provides limited evidence of conviction-shift or strategic repositioning.

David H Wang sells 131,250 shares at $26.57–$27.65 for $3.5M, reducing ACMR stake by 16.3% post-transaction to 672.7K shares

David H Wang executed 4 separate sales totaling 131,250 shares for $3,546,554.34 on 2025-03-11 through 2025-03-13, with a blended average price of $27.02. Post-transaction, Wang retains 672,708 shares (672.7K shares), down 16.3% from pre-transaction holdings of 803,958 shares. Across his cross-ticker track record of 18 prior sells, the insider's well-timed rate is 61.11%, suggesting moderately disciplined exit timing historically. At ACMR specifically, Wang's 5 prior trades show mixed outcomes: 2 of the 5 prior sells achieved negative 90-day returns (well-timed exits), while 3 showed gains (poorly timed). The stock currently trades at $27.44, down 14.4% from its 52-week high of $32.04, yet up 19.0% over the past 30 days and up 76.0% over 90 days. Fundamentals are robust: revenue of $203,976,000.00, net income of $30,904,000.00, annual revenue growth of +40.2%, and a P/E of 3.34. The filing itself contains no timing flag (10b5-1 plan indicator) that would preclude timing analysis.

David H Wang sells 56,250 shares of ACMR for $1.0M under pre-arranged 10b5-1 plan

David H Wang executed 2 separate sales totaling 56,250 shares for $1,006,086.84 on 2024-11-26, reducing his holdings from 710,506 shares to 654,256 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-05-14, meaning the sales were scheduled and non-discretionary. The 7.9% reduction in holdings was executed at a blended average price of $17.89 per share. Since this sale follows a scheduled plan rather than a discretionary decision, the transaction represents routine capital deployment under a pre-existing agreement rather than a signal tied to Wang's current assessment of the company.

ACMR CFO David H Wang sells 56,250 shares at $19.08 under 10b5-1 plan; retains 710,506 shares

David H Wang, identified in the remarks as holding a senior officer position (CFO per SEC records), executed a sale of 56,250 shares on 2024-11-22 at $19.08 for a total value of $1,073,250.00, reducing his holdings from 766,756 shares to 710,506 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-05-14, meaning it was scheduled in advance and does not reflect discretionary market judgment at the time of execution. Wang continues to hold 710,506 shares post-transaction, representing substantial ongoing exposure to the company. The 7.3% reduction in share count is consistent with gradual liquidity management under a pre-set plan rather than a signal of sudden conviction change.